Food and Drug Administration Commissioner Marty Makary resigned Tuesday after roughly 13 months in office, ending a tenure marked by policy reversals, friction with senior administration officials, and mounting complaints from pharmaceutical executives, vaping lobbyists, and pro-life groups alike. President Trump confirmed the departure on Truth Social and named Kyle Diamantas, the FDA's deputy commissioner for food, as acting head of the agency.
The resignation was not a surprise inside the West Wing. The Wall Street Journal reported that Trump signed off last week on a plan to fire Makary after top administration officials concluded that months of turmoil had made his position untenable. Rather than wait for the axe, the former Johns Hopkins surgeon offered his resignation effective Tuesday.
The real question is not whether Makary deserved to go. It is whether the FDA, an agency that touches every drug, device, and food product Americans consume, can survive this level of leadership churn without real cost to the public.
Makary arrived in Washington as a reformer. He championed causes popular with Robert F. Kennedy Jr.'s Make America Healthy Again movement and listed reducing drug-review times among his accomplishments. In a resignation text message Trump posted publicly, Makary wrote that he had announced 50 major FDA reforms, and that Joe Biden's FDA had none, as AP News reported.
But reform ambitions collided with political reality on multiple fronts. In February, Makary refused to authorize blueberry and mango vape flavors from Glas, a Los Angeles manufacturer. The decision drew sharp pushback from Trump, who had grown frustrated with what he saw as foot-dragging on flavored vapes and other nicotine products. Makary reversed course and authorized the flavors. Just days before his resignation, the FDA unveiled a broader new policy allowing some nicotine vapes and pouches not yet authorized by the agency to enter the market.
The vape fight was only one front. Anti-abortion groups including Susan B. Anthony Pro-Life America called for Makary to be fired after he failed to produce a promised safety study of the abortion pill mifepristone. Makary said he could have stalled approval of a generic form of the pill but chose not to, a decision that satisfied neither side of the debate.
Sen. Bill Cassidy, the Louisiana Republican who chairs the committee that must approve Makary's successor, framed the departure in blunt terms:
"Dr. Makary was part of a broader symptom of an administration that has not paid attention to pro-life issues. I care deeply about life, and I anticipate the next FDA nominee shall as well."
That is a pointed warning, not just about Makary, but about whoever comes next.
HHS Secretary Kennedy publicly praised Makary on his way out, writing on social media that Makary "took on entrenched interests, challenged the status quo, and never lost sight of the American people we serve." He added that Makary "pushed forward critical reforms and helped advance our mission to Make America Healthy Again."
Behind the scenes, the picture looked different. Newsmax cited an administration official telling Politico that "it was really Secretary Kennedy himself who made this decision," with the White House signing off. The Journal reported that Kennedy had considered installing someone else to run the FDA as far back as last year, with Makary remaining as a figurehead, a plan that apparently never materialized but signaled deep dissatisfaction.
Some inside the White House came to regard Makary as a rogue agent. His policy fights with top HHS and White House officials accumulated over months. The combination of pharmaceutical-industry complaints, pro-life anger, and internal management struggles after Department of Government Efficiency-led layoffs left Makary without a reliable base of support inside the administration.
Makary's exit is the latest in a pattern of senior officials departing the administration under pressure, raising fair questions about whether the White House vetting and management process is setting appointees up for success, or for short, chaotic tenures.
Trump's choice of Diamantas as acting commissioner drew immediate fire from pro-life activists. Anti-abortion leader Lila Rose posted on X:
"We cannot allow someone who represented Planned Parenthood to oversee rules surrounding the deadly abortion pill mifepristone."
The criticism stems from work Diamantas's former law firm did representing Planned Parenthood in a dispute involving one of its clinics slated to open at Florida's Kissimmee Health Center medical complex. White House spokesman Kush Desai pushed back directly:
"Kyle Diamantas was a junior legal associate who was assigned to that case by his superiors. He expressed his objections to representing Planned Parenthood, based on his personal convictions, and ultimately removed himself from the case."
That explanation may satisfy some critics. It will not satisfy all of them, particularly those who watched Makary's tenure end in part because of the unresolved mifepristone safety review. The pro-life movement's patience with FDA leadership is running thin, and Cassidy's committee will be watching closely.
The personnel churn extends well beyond the FDA. Navy Secretary John Phelan recently departed in another Cabinet-level exit that followed a similar resign-and-replace sequence.
Drug and biotech executives had pushed in recent weeks for a steady hand at the FDA. John Crowley, president and chief executive of the Biotechnology Innovation Organization, did not mince words after Makary's departure:
"What we need now is strong, stable and science-driven leadership at the FDA. We are losing the biotech race with China. FDA must be strengthened immediately."
That plea reflects a real concern. The FDA's regulatory decisions affect billions of dollars in investment, drug-approval timelines, and America's competitive position against China's rapidly expanding biotech sector. Every month of leadership uncertainty is a month competitors gain ground.
Just The News described Makary's tenure as tumultuous, noting controversies spanning abortion drugs, vape approvals, and the broader MAHA movement. The breadth of those disputes underscores how many constituencies the next FDA commissioner will need to manage simultaneously.
The administration's broader pattern of federal personnel shakeups means the FDA's instability is not happening in isolation. Across multiple agencies, leadership turnover has created gaps that career staff and acting officials must fill, often without the authority or political backing to make lasting decisions.
Not everyone celebrated Makary's departure. Vani Hari, the MAHA influencer known as the Food Babe, posted on X praising the outgoing commissioner:
"Washington doesn't know what to do with people who can't be bought. Dr. Marty Makary was one of the few people inside Washington willing to challenge the corporate capture of our health agencies. He questioned the status quo, stood up to powerful interests, and gave millions of Americans hope that the FDA could finally put public health over pharmaceutical and chemical industry profits."
That framing, Makary as a reformer crushed by entrenched interests, will appeal to the populist wing of the MAHA movement. But it sits uneasily alongside the fact that Makary's own reversals on vape policy and his failure to deliver the promised mifepristone review gave his critics inside the administration the ammunition they needed.
Trump himself struck a measured tone. "Marty is a terrific guy and he's going to go on and lead a good life. He was having some difficulty," the president said. When asked directly whether he fired Makary or asked him to resign, Trump told reporters, "I don't want to say, but Marty's a great guy." He added: "Everybody wants that job."
Makary's departure follows a now-familiar sequence at HHS. CDC Director Susan Monarez was ousted last summer. Deputy Secretary Jim O'Neill was removed in February. The agency that oversees American health policy has cycled through senior leaders at a pace that makes continuity difficult and accountability elusive.
Personnel departures across the administration, including the recent exit of a DHS spokeswoman just weeks after joining, suggest the problem is structural, not confined to any single agency or personality.
Whoever Trump nominates as Makary's permanent replacement will face Senate confirmation in front of Cassidy's committee, a chairman who has now publicly demanded a pro-life commitment from the next nominee. The biotech industry wants regulatory speed and predictability. The MAHA movement wants an end to what it sees as corporate capture. Pro-life groups want action on mifepristone. The vaping industry wants market access.
Satisfying all of those constituencies simultaneously may be impossible. Makary's 13-month tenure proved that much.
The FDA regulates products that account for roughly a quarter of every dollar Americans spend. It deserves a leader who can last longer than a calendar year, and an administration willing to back that leader when the pressure mounts.